Navigation Links
NovaVision CEO Named Presenter at the AdvaMed 2008 Conference
Date:9/8/2008

BOCA RATON, Fla., Sept. 8 /PRNewswire/ -- NovaVision today announced that the company has been selected to present at the prestigious AdvaMed 2008: The MedTech Conference (http://www.advamed2008.com), on Monday, September 22, 2008 in Washington, DC.

During the presentation, which falls in the "Next Generation" category, Mr. Rudy Mazzocchi, the newly appointed chief executive officer of NovaVision, will address the increasing use of Vision Restoration Therapy (VRT) among U.S. and global healthcare providers. VRT is a non-invasive medical device cleared by the United States Food & Drug Administration to help restore vision to the millions of underserved people living with impaired sight caused by a stroke or traumatic brain injury (TBI).

Using the science of neuroplasticity -- the brain's ability to rewire itself -- VRT is an in-home personalized restoration therapy that uses light-based stimuli to gradually activate adjacent neurons in the brain responsible for vision. Each patient receives a program that is entirely customized to their own unique visual field deficits. Every month, the patient receives an advanced program to correlate to individual progress. Clinical trials show that nearly 70-80% of all patients show improved vision following therapy, regardless of how long ago their stroke or TBI occurred.

About NovaVision, Inc.

NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically-based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. FDA-cleared in 2003, NovaVision's Vision Restoration Therapy devices work by enhancing neuroplasticity -- the brain's ability to adapt and form new connections to compensate for injury. NovaVision's diagnostic program maps areas where vision may be improved, and the therapy program targets and stimulates regions within the brain's vision-processing areas.

NovaVision VRT(R) is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of patients who underwent VRT for an initial six-month treatment period showed measurable improvements in their vision.

VRT is currently offered at leading neurological, eye and rehabilitation centers nationwide. For more information, please visit http://www.novavision.com or call 1.888.205.0800.

Contacts:

Ellie Kline, Edelman on behalf of NovaVision

Ph. 212-704-4528

Email: elinor.kline@edelman.com


'/>"/>
SOURCE NovaVision, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer
2. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
3. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
4. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
5. Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc
6. Baxa Corporation Named to Inc. 5000 for Second Consecutive Year as One of the Fastest-Growing Private Companies in the US
7. IDIS Opens New American Office in Response to Industrys Growing Need for Pre-Launch Named Patient Programs
8. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
9. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):